First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials.
Thierry LandreJean-Baptiste AssiéKader ChouahniaGaetan Des GuetzJean-Bernard AuliacChristos ChouaidPublished in: Expert review of anticancer therapy (2024)
PROSPERO CRD42024508055.
Keyphrases
- tyrosine kinase
- phase iii
- small cell lung cancer
- epidermal growth factor receptor
- advanced non small cell lung cancer
- open label
- double blind
- placebo controlled
- clinical trial
- phase ii
- squamous cell carcinoma
- radiation therapy
- chronic myeloid leukemia
- randomized controlled trial
- locally advanced
- study protocol
- wild type